Products

Products A-Z

Through the use of natural elements, science and clinical trials, we are able to provide patients with cutting-edge pharmaceuticals to improve overall well-being.

Our product areas

CimetrA®
Designed for the treatment of acute lung injury and acute respiratory distress syndrome (ARDS), currently in Phase 2B studies in Israel and already generates revenues through the early access schemes.
CimetrA® is a phyto medicine based on natural ingredients from Curcumin & Boswellia serrata, delivered in the nanoparticle delivery system, has demonstrated effectiveness in arresting the cytokine storm in COVID-19 patients.
CimetrA® uses an enhanced delivery system technology, a platform to deliver natural ingredients more effectively in higher concentrations to the cells, improving the bioavailability of natural ingredients;
CimetrA® successfully met all its primary and secondary study endpoints (100% of patients in the treatment group) and all FDA requirements for a diversity of patients;
None of the patients in the treatment group required additional oxygen, mechanical ventilation or admission to intensive care.
Compounds
Combination of Curcumin & Boswellia Serrata
Route of Administration
Medical oral sprayc
Mechanism of Action
Immunomodulation in inflammatory conditions
Administration
Twice a day for two days
Dose
2 ml per day
Storage Conditions
Stored in the fridge (between 2-8°C)
CannEpil®
Designed as a seizure control treatment for patients with refractory epilepsy and cerebral palsy, entering Phase 2B under the FDA in 2025, generates revenues through the early access schemes.
CannEpil® is a phyto medicine based on phytocannabinoids currently investigated for the treatment of refractory epilepsy. Produced from two proprietaries, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.
The first medicinal cannabis product eligible for patients in Ireland and fully covered under Ireland’s Primary Care Reimbursement Service as part of the country’s Medicinal Cannabis Access Programme (MCAP).
Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes

Argent Biopharma’s first pharmaceutical-grade product currently investigated for drug-resistant (refractory) epilepsy, which accounts for approximately 25% of the people diagnosed with epilepsy

6 000 000
people with epilepsy in Europe
25%
people with epilepsy have a drug resistance epilepsy (DRE) form
200 000
The estimated epilepsy patients in Australia
200 000
The estimated population people with DRE at the launch of marketing authorisation (in Europe and Australia)
CogniCann®
Designed to improve the quality of living in Dementia and Alzheimer patients, completed phase 2A studies in Australia.
CogniCann® is a phyto medicine based on phytocannabinoids currently investigated as a treatment for the symptoms associated with dementia and Alzheimer’s.
The efficacy of CogniCann® was assessed using the following three criteria: The participant’s NPI-NH Score using the Neuropsychiatric Inventory – Nursing Home Version (NPI-NH) Questionnaire, based on responses from the participants, and caregivers involved in their daily care.
Patients in the Placebo group experienced a deterioration in their condition, based on their NPI-NH score, compared with the stable neuropsychiatric profile of those patients treated with CogniCann®. Patients’ aggressive behavior improved by 13%, compared with the Placebo Group, which improved by 4%.
This important finding indicates not only improvement in the health status of the patients but also the improved quality of life of the families and caregivers taking care of dementia patients.
1 000 000
people with mild dementia in Europe and Australia
5 years
Expected time to marketing authorisation
Compounds
Cannabidiol (CBD) & (-)-trans-r9-tetrahydrocannabinol (THC) in a 3:5 ratio, dissolved in MCT oil
Route of Administration
Medical oral spray
Storage Conditions
Stored in the fridge (between 2-8°C)

Drug safety

Timely reporting to Drug Safety is critical for compliance with regulatory requirements. If you are a patient reporting any adverse events or if you have questions about your condition, please contact your healthcare professional immediately.

Patient safety is paramount to Argent Biopharma . It is both our ethical regulatory responsibility and duty to monitor the safety of the medicines we develop, from their preclinical stage through clinical testing and prescribing.